Skip to Main Content
TABLE 2

Effects of des-fluoro-sitagliptin and glipizide on plasma parameters in the HFD/STZ mouse model

A1C (%)GLP-1intact (pmol/l)Glucagon (pg/ml)Triglyceride (mg/dl)FFA (mmol/l)
Vehicle 7.5 ± 0.2 2.1 ± 0.4 92 ± 14 400 ± 35 3.4 ± 0.4 
Des-fluoro-sitagliptin 5.6 ± 0.3* 9.9 ± 3.4* 51 ± 6* 196 ± 32* 1.3 ± 0.2* 
Glipizide 7.2 ± 0.2 1.8 ± 0.5 100 ± 15 322 ± 43 2.4 ± 0.3 
Nondiabetic control 4.5 ± 0.1* 1.9 ± 0.4 52 ± 4* 110 ± 10* 0.6 ± 0.1* 
A1C (%)GLP-1intact (pmol/l)Glucagon (pg/ml)Triglyceride (mg/dl)FFA (mmol/l)
Vehicle 7.5 ± 0.2 2.1 ± 0.4 92 ± 14 400 ± 35 3.4 ± 0.4 
Des-fluoro-sitagliptin 5.6 ± 0.3* 9.9 ± 3.4* 51 ± 6* 196 ± 32* 1.3 ± 0.2* 
Glipizide 7.2 ± 0.2 1.8 ± 0.5 100 ± 15 322 ± 43 2.4 ± 0.3 
Nondiabetic control 4.5 ± 0.1* 1.9 ± 0.4 52 ± 4* 110 ± 10* 0.6 ± 0.1* 

Data are means ± SE (n = 8–10). Nondiabetic control mice or diabetic HFD/STZ mice were treated with HFD containing vehicle, des-fluoro-sitagliptin (1.1% admixture), or glipzide (0.02% admixture) for 10 weeks. A1C, plasma GLP-1, glucagon, triglycerides, and FFAs (FFA levels were measured under the fed condition).

*

P < 0.05 compared with the vehicle-treated group.

Close Modal

or Create an Account

Close Modal
Close Modal